Literature DB >> 15795295

Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice.

Patrick M Smith1, Shannon M Kahan, Colin B Rorex, Jens von Einem, Nikolaus Osterrieder, Dennis J O'Callaghan.   

Abstract

Wild-type equine herpesvirus 1 (EHV-1) strains express a large (250-kDa) glycoprotein, gp2, that is encoded by EUs4 (gene 71) located within the unique short region of the genome. DNA sequence analysis revealed that EUs4 of the pathogenic EHV-1 strain RacL11 is an open reading frame of 2,376 bp that encodes a protein of 791 amino acids. The attenuated EHV-1 vaccine strain KyA harbors an in-frame deletion of 1,242 bp from bp 222 to 1461 and expresses a truncated gp2 of 383 amino acids. To determine the relative contribution of gp2 to EHV-1 pathogenesis, we compared the course of respiratory infection of CBA mice infected with either wild-type RacL11, attenuated KyA, or a recombinant KyA that expresses the full-length gp2 protein (KyARgp2F). Mice infected with KyA lost a negligible amount of body weight (0.18% total weight loss) on day 1 postinfection and regained weight thereafter, whereas mice infected with KyARgp2F or RacL11 steadily lost weight beginning on day 1 and experienced a 20 and 18% loss in body weight, respectively, by day 3. Immunohistochemical and flow cytometric analyses revealed higher numbers of T and B lymphocytes and an extensive consolidation consisting of large numbers of Mac-1-positive cells in the lungs of animals infected with KyARgp2F compared to animals infected with KyA. RNase protection analyses revealed increased expression of numerous cytokines and chemokines, including interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor alpha, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, MIP-2, interferon gamma-inducible protein, monocyte chemotactic protein 1, and T-cell activation gene 3 at 12 h postinfection with KyARgp2F. Three independent DNA array experiments confirmed these results and showed a 2- to 13-fold increase in the expression of 31 inflammatory genes at 8 and 12 h postinfection with KyARgp2F compared to infection with KyA. Taken together, the results indicate that expression of full-length gp2 is sufficient to restore full respiratory virulence to the attenuated KyA strain and raise caution concerning the inclusion of full-length gp2 in the development of EHV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795295      PMCID: PMC1069573          DOI: 10.1128/JVI.79.8.5105-5115.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Characterization of two equine herpesvirus (EHV) isolates associated with neurological disorders in horses.

Authors:  H Meyer; P Thein; P Hübert
Journal:  Zentralbl Veterinarmed B       Date:  1987-09

2.  Characterization of the high Mr glycoprotein (gP300) of equine herpesvirus type 1 as a novel glycoprotein with extensive O-linked carbohydrate.

Authors:  G R Whittaker; L A Wheldon; L E Giles; J M Stocks; I W Halliburton; R A Killington; D M Meredith
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

3.  Characterization of the major glycoproteins of equine herpesviruses 4 and 1 and asinine herpesvirus 3 using monoclonal antibodies.

Authors:  B S Crabb; G P Allen; M J Studdert
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

4.  Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses.

Authors:  F Bürki; W Rossmanith; N Nowotny; C Pallan; K Möstl; H Lussy
Journal:  Vet Q       Date:  1990-04       Impact factor: 3.320

5.  Equine herpesvirus 1 infection of horses: studies on the experimentally induced neurologic disease.

Authors:  T A Jackson; B I Osburn; D R Cordy; J W Kendrick
Journal:  Am J Vet Res       Date:  1977-06       Impact factor: 1.156

6.  Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain.

Authors:  D Hannant; D M Jessett; T O'Neill; C A Dolby; R F Cook; J A Mumford
Journal:  Res Vet Sci       Date:  1993-05       Impact factor: 2.534

7.  The equine herpesvirus type 1 (EHV-1) homolog of herpes simplex virus type 1 US9 and the nature of a major deletion within the unique short segment of the EHV-1 KyA strain genome.

Authors:  C C Flowers; D J O'Callaghan
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

8.  The open reading frames 1, 2, 71, and 75 are nonessential for the replication of equine herpesvirus type 1 in vitro.

Authors:  Y Sun; S M Brown
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

9.  Open reading frames encoding a protein kinase, homolog of glycoprotein gX of pseudorabies virus, and a novel glycoprotein map within the unique short segment of equine herpesvirus type 1.

Authors:  C F Colle; C C Flowers; D J O'Callaghan
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

10.  The DNA sequence of equine herpesvirus-1.

Authors:  E A Telford; M S Watson; K McBride; A J Davison
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

View more
  12 in total

1.  Immunization with Attenuated Equine Herpesvirus 1 Strain KyA Induces Innate Immune Responses That Protect Mice from Lethal Challenge.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

2.  Properties of an equine herpesvirus 1 mutant devoid of the internal inverted repeat sequence of the genomic short region.

Authors:  ByungChul Ahn; Yunfei Zhang; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virology       Date:  2010-12-21       Impact factor: 3.616

3.  Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  Antiviral Res       Date:  2019-06-25       Impact factor: 5.970

4.  Proteomic analysis of pathogenic and attenuated alcelaphine herpesvirus 1.

Authors:  Inga Dry; David M Haig; Neil F Inglis; Lisa Imrie; James P Stewart; George C Russell
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

5.  CCL3 and viral chemokine-binding protein gg modulate pulmonary inflammation and virus replication during equine herpesvirus 1 infection.

Authors:  Gerlinde R Van de Walle; Kaori Sakamoto; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

6.  The IR4 auxiliary regulatory protein expands the in vitro host range of equine herpesvirus 1 and is essential for pathogenesis in the murine model.

Authors:  Jonathan E Breitenbach; Paul D Ebner; Dennis J O'Callaghan
Journal:  Virology       Date:  2008-11-13       Impact factor: 3.616

7.  The UL4 protein of equine herpesvirus 1 is not essential for replication or pathogenesis and inhibits gene expression controlled by viral and heterologous promoters.

Authors:  Robert A Charvat; Jonathan E Breitenbach; ByungChul Ahn; Yunfei Zhang; Dennis J O'Callaghan
Journal:  Virology       Date:  2011-02-15       Impact factor: 3.513

8.  The full genome sequences of 8 equine herpesvirus type 4 isolates from horses in Japan.

Authors:  Satoko Izume; Rikio Kirisawa; Kenji Ohya; Aiko Ohnuma; Takashi Kimura; Tsutomu Omatsu; Yukie Katayama; Tetsuya Mizutani; Hideto Fukushi
Journal:  J Vet Med Sci       Date:  2016-11-14       Impact factor: 1.267

9.  Comparative Genomic Sequencing and Pathogenic Properties of Equine Herpesvirus 1 KyA and RacL11.

Authors:  Akhalesh K Shakya; Dennis J O'Callaghan; Seong K Kim
Journal:  Front Vet Sci       Date:  2017-12-11

10.  CCL2 and CCL5 driven attraction of CD172a+ monocytic cells during an equine herpesvirus type 1 (EHV-1) infection in equine nasal mucosa and the impact of two migration inhibitors, rosiglitazone (RSG) and quinacrine (QC).

Authors:  Jing Zhao; Katrien C K Poelaert; Jolien Van Cleemput; Hans J Nauwynck
Journal:  Vet Res       Date:  2017-02-27       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.